Syngene International financials

·Pharma & HealthChart ›
Latest results Q2 FY27 · Jul–Sep 2026
Revenue
₹833cr−8.6% on Q2 FY26
Net profit
₹32.2cr−52.0% on Q2 FY26
EBITDA margin
17.7%−4.2 pts on Q2 FY26
EPS
₹0.80−52.1% on Q2 FY26

Quarterly results

Every quarter ›
₹ croreQ2 FY27Q2 FY26Change
Revenue833911−8.6%
EBITDA147200−26.1%
EBITDA margin17.7%21.9%−4.2 pts
Profit before tax47.085.2−44.8%
Net profit32.267.1−52.0%
EPS₹0.80₹1.67−52.1%

Over time

Q2 FY27 · Jul–Sep 2026latest
Revenue₹833 crNet profit₹32.2 crNet margin3.9%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
16,553————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
529685978599914
9.49.4120142575
16,033————
3,5223,7393,6423,4893,193
—+2.6%+4.4%+9.3%—
7519191,0421,014934
21.3%24.6%28.6%29.1%29.3%
302466609589568
186317496510464
5.3%8.5%13.6%14.6%14.5%
₹4.62₹7.86₹12.32₹12.66₹11.53
—−36.2%−2.7%+9.8%—
—9151,1681,042824
—−368−770−511−518
547547398531305
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SYNGENE₹410.85

Syngene International Ltd.

· Pharma & Health
₹ CrorePeersSAILIFEDIVISLABWOCKPHARMAGLANDASTERDMPPLPHARMACOHANCELALPATHLABMcap ₹16,553 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————16,553.1
- Cash, Equiv & ST Investments913.9598.9977.6684.7529.2
+ Total Debt575.3141.7119.69.49.4
Enterprise Value————16,033.3
Revenue3,192.93,488.63,642.43,738.73,522.3
Growth %, YoY—+9.3+4.4+2.6—
EBITDA934.41,014.41,041.8918.5750.8
Margin %29.2629.0828.6024.5721.32
EBIT567.9588.5609.2465.6301.7
Net Income464.4510.0496.2316.7186.1
Margin %14.5414.6213.628.475.28
EPS, Adj (current shares)11.5312.6612.327.864.62
Growth %, YoY—+9.8-2.7-36.2—
Cash from Operations823.51,042.11,167.6915.2—
Capital Expenditures-518.3-510.8-770.1-368.2—
Free Cash Flow305.2531.3397.5547.0547.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Syngene International financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Syngene International (NSE: SYNGENE) had a market capitalisation of ₹16,091 crore at the 29 October 2026 close (₹398.60 a share), a PE ratio of 86.5 on the last four quarters' profit and a price-to-book ratio of 3.31. In FY26 its consolidated net profit was ₹317 crore on revenue of ₹3,739 crore; in Q2 FY27 (July–September 2026) it was ₹32.2 crore, down 52.0% year on year. Its debt-to-equity ratio was 0.01 on 30 September 2026. Promoters held 52.59% of the shares on 30 September 2026.

Share price used
₹398.60 · 29 October 2026 close
Latest balance sheet
30 September 2026
Shareholding pattern
30 September 2026

Syngene International at a glance · consolidated

Market cap
₹16,091 Crat ₹398.60 · 29 Oct close
PE ratio (last 4 quarters)
86.550.8 on FY26 profit
Price to book (PB)
3.31book value ₹120.36 a share
ROE (FY26)
6.6%−4.4 pts vs FY25ROCE 8.5%
Debt to equity
0.01net cash ₹463 Cr
Promoter holding
52.59%unchanged vs 30 Jun 202630 September 2026
Dividend yield
0.31%₹1.25 a share in 12 months
Net worth
₹4,859 Cr+2.6% vs 30 Sep 202530 September 2026
Free cash flow (FY26)
₹547 Cr+37.6% vs FY25

Questions

What is the Syngene International PE ratio today?

Syngene International's PE ratio is 86.5 at the 29 October 2026 close (₹398.60 a share): a market capitalisation of ₹16,091 crore divided by consolidated net profit of ₹186 crore over the last four quarters (Q3 FY26 to Q2 FY27). On FY26 net profit (₹317 crore) it is 50.8. These four quarters include net exceptional items of −₹96.8 crore (one-off charges reported separately), so the ratio on recurring profit would differ.

What is the Syngene International PB ratio (price to book value)?

Syngene International's price-to-book (PB) ratio is 3.31 at the 29 October 2026 close: a market capitalisation of ₹16,091 crore divided by shareholders' equity (book value) of ₹4,859 crore on 30 September 2026. That is a book value of ₹120.36 per share against a share price of ₹398.60.

What is the Syngene International ROE and ROCE?

In FY26, Syngene International's return on equity (ROE) was 6.6% and its return on capital employed (ROCE) was 8.5%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 11.1% and ROCE 11.7%.

What is the Syngene International market cap?

Syngene International's market capitalisation was ₹16,091 crore at the 29 October 2026 close: 40.37 crore shares at ₹398.60 each.

What is the Syngene International EPS?

Syngene International's basic earnings per share (EPS) were ₹7.87 in FY26, against ₹12.35 in FY25. Over the last four quarters (Q3 FY26 to Q2 FY27) they add up to ₹4.63.

What is the Syngene International dividend in 2026 and its record date?

In 2026, Syngene International has declared one dividend: ₹1.25 with record date 26 June 2026 and ex-date 25 June 2026.

Is Syngene International debt free?

No. Syngene International had borrowings of ₹67.2 crore on 30 September 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.01. Its cash and current investments were ₹530 crore, so it held net cash of ₹463 crore.

What is the Syngene International debt to equity ratio?

Syngene International's debt-to-equity ratio was 0.01 on 30 September 2026: borrowings of ₹67.2 crore against total equity of ₹4,859 crore. A year earlier, on 30 September 2025, it was 0.03.

What is the Syngene International promoter holding?

Promoters held 52.59% of Syngene International on 30 September 2026, unchanged from the previous quarter and down 0.09 percentage points from 52.68% a year earlier, according to the shareholding pattern filed with NSE.

What is the Syngene International net worth?

Syngene International's net worth — shareholders' equity in its consolidated balance sheet — was ₹4,859 crore on 30 September 2026, up 2.6% from ₹4,735 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹16,091 crore at the 29 October 2026 close.

What is the Syngene International book value per share?

Syngene International's book value per share was ₹120.36 on 30 September 2026: shareholders' equity of ₹4,859 crore divided by the 40.37 crore shares in issue, up 2.4% from ₹117.52 a year earlier. The share price at the 29 October 2026 close was ₹398.60.

What is the Syngene International dividend yield?

Syngene International's dividend yield is 0.31% at the 29 October 2026 close: dividends of ₹1.25 a share that went ex-dividend in the 12 months before that day, divided by the share price of ₹398.60. They were ₹1.25 on 25 June 2026.

What is the Syngene International shareholding pattern?

On 30 September 2026, Syngene International's shares were held by promoters 52.59%, foreign portfolio investors (FII/FPI) 10.14%, domestic institutions (DII) 29.30% (including mutual funds at 27.10%) and retail and other non-institutional investors 7.56%. Over the year, FII holding was down 6.17 percentage points from 16.31% and DII holding was up 4.68 percentage points from 24.62%.

How does Syngene International compare with its peers?

On FY26 consolidated figures, against Sai Life Sciences, Divi's Labs and Wockhardt: Syngene International's operating margin of 12.5% is the lowest of the four (Sai Life Sciences 21.2%, Divi's Labs 28.2%, Wockhardt 12.6%; peer average 20.7%); its return on equity of 6.6% is the third highest of the four (Sai Life Sciences 15.1%, Divi's Labs 16.2%, Wockhardt 4.6%; peer average 12.0%).

How does the Syngene International PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, Syngene International's PE ratio is 50.8, the lowest of the four: Sai Life Sciences 91.0, Divi's Labs 99.7 and Wockhardt 146.2, a peer average of 112.3. Each is the company's market capitalisation at that price divided by its FY26 net profit.

What is the Syngene International free cash flow?

In FY26, Syngene International generated ₹915 crore of cash from operations and spent ₹368 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹547 crore. In FY25 it was ₹398 crore.

What are the Syngene International latest quarterly results?

Syngene International's latest results are for Q2 FY27 (July–September 2026), filed on 27 October 2026: consolidated net profit ₹32.2 crore, down 52.0% from ₹67.1 crore in Q2 FY26; revenue from operations ₹833 crore, down 8.6% year on year.

What is the Syngene International revenue and profit in FY26?

In FY26 (April 2025–March 2026), Syngene International's consolidated net profit was ₹317 crore, down 36.2% from ₹496 crore in FY25, on revenue from operations of ₹3,739 crore (up 2.6%). Over three years, from FY23, net profit was down 31.8%.

When are the Syngene International next results?

Syngene International has reported Q2 FY27. Its next results, for Q3 FY27 (October–December 2026), are due by 14 February 2027 under SEBI's 45-day rule; the company notifies the board-meeting date at least two working days before.

Syngene International vs Sai Life Sciences: how do they compare?

In FY26, Syngene International earned net profit of ₹317 crore on revenue of ₹3,739 crore, against ₹349 crore on ₹2,192 crore for Sai Life Sciences. Syngene International's operating margin was 12.5% (Sai Life Sciences 21.2%) and its return on equity 6.6% (Sai Life Sciences 15.1%). At the 29 October 2026 close, Syngene International's market capitalisation was ₹16,091 crore against ₹31,752 crore for Sai Life Sciences, and its PE ratio on FY26 profit 50.8 against 91.0.

Where do these Syngene International figures come from?

From Syngene International's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.